FDA committee to discuss Teva's asthma biologic

FDA's Pulmonary-Allergy Drugs Advisory Committee will meet Dec. 9 to discuss a BLA for reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to reduce exacerbation, relieve symptoms and impr...